Core Viewpoint - The company focuses on developing pediatric medications, emphasizing the need for tailored drug solutions for children and maintaining high-quality standards in design and production [2] Group 1: Product Development - The subsidiary, Dain Pharmaceutical, has received drug registration certificates for sodium valproate oral solution and sustained-release clonidine tablets [2] - The company has initiated clinical trials for the inhalation aerosol of ipratropium bromide, indicating a commitment to expanding its product pipeline [2] Group 2: Strategic Focus - The company aims to enhance its core competitiveness by continuously developing 1-2 new pediatric-specific medications each year [2] - The research and development efforts are directed towards addressing clinical needs in mental health, respiratory, and digestive fields, aligning with children's health and nutritional requirements [2]

Core Viewpoint - The company, Watson, has received approval from the National Medical Products Administration for a clinical trial of a new drug, indicating a significant step in its product development pipeline [1] Group 1: Drug Approval - Watson's subsidiary, Dain Pharmaceutical, has been granted a "Drug Clinical Trial Approval Notice" for the drug named Isopropyl Bromide Inhalation Aerosol [1] - The drug is classified as a Class 4 chemical drug and is intended for the prevention and treatment of respiratory difficulties associated with chronic obstructive airway diseases, chronic bronchitis with or without emphysema, and mild to moderate bronchial asthma in both children and adults [1] Group 2: Next Steps - Following the approval of the clinical trial, the company must conduct clinical trials before applying for production and market approval from the National Medical Products Administration [1]